Press release
Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | AIMOVIG, Fremanezumab, LBR-101, Atogepant, Galcanezumab, Eptinezumab
Migraine Market
(Albany, USA) DelveInsight's "Migraine Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the Migraine market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Migraine market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Migraine Market Forecast [https://www.delveinsight.com/report-store/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Some of the key facts of the Migraine Market Report:
* The Migraine market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
* All participants who had a headache within the previous 12 months prior to the survey between October 2019 and March 2020 were included in the BURDEN 2020 study, which was developed by the RKI and conducted by the market and social research institute USUMA GmbH. According to the survey, 40.4% of men and 57.5% of women reported having headaches in the previous 12 months. In both men and women, 6.0% and 1.2%, respectively, suffered from migraines
* Migraine is the most prevalent neurological condition, according to German research community funding headache research in Essen 2021. Around 14% of German women and 8% of German men are affected. About 2% of people have a chronic form of the condition
* Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
* Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
* The Migraine epidemiology based on gender analyzed that the prevalence of migraine in female is slightly higher than male
* The Migraine market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Migraine pipeline products will significantly revolutionize the Migraine market dynamics.
* On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE).
* On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens.
* On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine
Migraine Overview
Migraine is a neurological disorder characterized by recurrent, debilitating headaches often accompanied by other symptoms such as nausea, vomiting, sensitivity to light, and sound. These headaches typically last from a few hours to several days and can significantly interfere with daily activities and quality of life. Migraines are believed to involve abnormal brain activity and changes in blood flow, although the exact cause is not fully understood. Certain factors such as genetics, hormonal fluctuations, environmental triggers, and underlying medical conditions may contribute to migraine development. There are several types of migraines, including with aura (preceded by sensory disturbances like flashes of light or tingling) and without aura. Migraine Diagnosis is based on a thorough medical history, symptom evaluation, and ruling out other possible causes of headaches. Treatment strategies for migraines include lifestyle modifications, such as identifying and avoiding triggers, as well as medications for acute relief and prevention. These may include pain relievers, triptans, anti-nausea drugs, preventive medications, and alternative therapies like acupuncture or biofeedback. A personalized approach to management, tailored to the individual's specific symptoms and triggers, is often necessary for effective migraine control.
Get a Free sample for the Migraine Market Report - https://www.delveinsight.com/sample-request/migraine-market [https://www.delveinsight.com/report-store/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Migraine Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Migraine Epidemiology Segmentation:
The Migraine market report proffers epidemiological analysis for the study period 2019-2034 in the 7MM segmented into:
* Total Prevalence of Migraine
* Prevalent Cases of Migraine by severity
* Gender-specific Prevalence of Migraine
* Diagnosed Cases of Episodic and Chronic Migraine
Download the report to understand which factors are driving Migraine epidemiology trends @ Migraine Epidemiology Forecast [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Migraine Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Migraine market or expected to get launched during the study period. The analysis covers Migraine market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Migraine Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Migraine Therapies and Key Companies
* AIMOVIG: Amgen
* Fremanezumab: Teva Pharmaceuticals
* Galcanezumab: Eli Lilly and Company
* propranolol LA: Anne Lindblad
* Atogepant: Allergan
* LBR-101: Teva Branded Pharmaceutical
* Atogepant: AbbVie
* Galcanezumab: Eli Lilly and Company
* Marcaine: Tian Medical Inc.
* Atogepant: Allergan
* Galcanezumab: Eli Lilly and Company
* Eptinezumab: H. Lundbeck A/S
* TNX-1900: Tonix Pharmaceuticals, Inc.
* IONIS-PKKRx (ISIS 546254): Ionis Pharmaceuticals, Inc.
Discover more about therapies set to grab major Migraine market share @ Migraine Treatment Market [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Migraine Market Report
* Study Period: 2020-2034
* Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
* Key Migraine Companies: Amgen, Teva Pharmaceuticals, Eli Lilly and Company, Anne Lindblad, Allergan, Teva Branded Pharmaceutical, AbbVie, Tian Medical Inc., Allergan, Eli Lilly and Company, H. Lundbeck A/S, Tonix Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., and others
* Key Migraine Therapies: AIMOVIG, Fremanezumab, propranolol LA, LBR-101, Atogepant, Galcanezumab, Marcaine, Atogepant, Galcanezumab, Eptinezumab, TNX-1900, IONIS-PKKRx (ISIS 546254), and others
* Migraine Therapeutic Assessment: Migraine current marketed and Migraine emerging therapies
* Migraine Market Dynamics: Migraine market drivers and Migraine market barriers
* Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Migraine Unmet Needs, KOL's views, Analyst's views, Migraine Market Access and Reimbursement
To know more about Migraine companies working in the treatment market, visit @ Migraine Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/migraine-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Contents
1. Migraine Market Report Introduction
2. Executive Summary for Migraine
3. SWOT analysis of Migraine
4. Migraine Patient Share (%) Overview at a Glance
5. Migraine Market Overview at a Glance
6. Migraine Disease Background and Overview
7. Migraine Epidemiology and Patient Population
8. Country-Specific Patient Population of Migraine
9. Migraine Current Treatment and Medical Practices
10. Migraine Unmet Needs
11. Migraine Emerging Therapies
12. Migraine Market Outlook
13. Country-Wise Migraine Market Analysis (2019-2034)
14. Migraine Market Access and Reimbursement of Therapies
15. Migraine Market Drivers
16. Migraine Market Barriers
17. Migraine Appendix
18. Migraine Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
On April 2024, AbbVie announced results of a Randomized, Double-Blind, Parallel-Group, and Active Controlled Trial with Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE).
On April 2024, Pfizer announced results of a Phase 4 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Episodic Migraine Prevention with Multiple Dosing Regimens.
On November 2023, AbbVie announced results of a Phase 2/3, Multicenter, Randomized, Double-Blind, Placebo Controlled, and Parallel-Group Study with an Active Treatment Extension to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Japanese Subjects with Episodic Migraine.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=migraine-market-forecast-2034-fda-ema-pdma-approvals-clinical-trials-therapies-epidemiology-and-companies-by-delveinsight-aimovig-fremanezumab-lbr101-atogepant-galcanezumab-eptinezumab]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/asco-conference-coverage
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Migraine Market Forecast 2034: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, Epidemiology and Companies by DelveInsight | AIMOVIG, Fremanezumab, LBR-101, Atogepant, Galcanezumab, Eptinezumab here
News-ID: 3497604 • Views: …
More Releases from ABNewswire
Startup Giftful Gems Builds Business Model Around Emotional Connection and Meani …
Giftful Gems represents innovative retail approach that prioritizes customer emotional satisfaction over traditional metrics, focusing on products that create joy and strengthen relationships through thoughtful gift-giving. The new online retailer targets consumers seeking alternatives to mass-market options while building business success through genuine care for customer outcomes.
The retail industry has traditionally measured success through quantitative metrics like sales volume, inventory turnover, and profit margins, often overlooking the qualitative outcomes that…
Joint Pain Rescue Platform Demonstrates How Digital Healthcare Can Prioritize Pa …
Joint Pain Rescue showcases innovative healthcare business model that prioritizes patient education and accessibility over traditional profit-driven approaches. The platform's free comprehensive course for joint pain management represents emerging trend toward value-based healthcare information that empowers patients while building sustainable businesses through genuine health outcomes rather than product sales.
The healthcare industry has long struggled with tensions between commercial objectives and patient welfare, often resulting in business models that prioritize revenue…
Author's Tranquility Press Presents: "Confessions of a Corgi Doodler" - A Whimsi …
Nancy Kondos' Delightful New Book Celebrates the Art of Imperfect Doodles and the Irresistible Charm of Corgis
Author's Tranquility Press is thrilled to announce the release of Confessions of a Corgi Doodler [https://www.amazon.com/Confessions-Corgi-Doodler-Nancy-Kondos/dp/1966972717/ref=tmm_pap_swatch_0?_encoding=UTF8&dib_tag=se&dib=eyJ2IjoiMSJ9.nrKIgvSORUypy55MCVfP6A.Y5mWYYbHvQvFWtTL1ag6iD8erODCj3RPU4WsPh-Bvdo&qid=1758212447&sr=1-1], a charming and beautifully illustrated book by author and artist Nancy Kondos. This heartwarming collection invites readers into a world where pens dance freely, lines wobble with personality, and Corgis come to life in the most unexpectedly joyful…
Author's Tranquility Press Presents: "A Parent's Guide for Educational Success f …
From choosing the right school and managing seasonal illnesses to nurturing resilience during family changes, this guide offers practical, heartfelt wisdom for raising confident, well-rounded learners.
Author's Tranquility Press is proud to announce the release of A Parent's Guide for Educational Success for Their Children [https://www.amazon.com/Parents-Guide-Educational-Success-Children-ebook/dp/B09VDKQ61G/ref=monarch_sidesheet_image] by Joann Falciani-a deeply insightful, compassionate, and immensely practical resource for parents navigating the often-overwhelming journey of their child's education.
Packed with real-world advice, actionable strategies,…
More Releases for Migraine
Leading Growth Driver in the Migraine Market Share in 2025: Rising Prevalence Of …
What Market Share dynamics are playing a key role in accelerating the growth of the migraine Market Share?
The migraine Market Share is projected to grow, driven by the rising occurrence of migraines. Migraines, a kind of headache that typically affects one side of the brain and causes intense, throbbing pain or a pulsing sensation, can be managed and relief can be provided via proper treatment. This treatment paves the way…
Emerging Acute Migraine Treatment Market Trend 2025-2034: Innovative CGRP Recept …
How Is the Acute Migraine Treatment Market Projected to Grow, and What Is Its Market Size?
The market size for acute migraine treatment has witnessed substantial growth in the past few years. Forecasts expect it to expand from $2.6 billion in 2024 to $2.91 billion in 2025, boasting a compound annual growth rate (CAGR) of 11.6%. Factors contributing to this growth in the historical period include the rising incidence of migraines,…
Key Influencer in the Migraine Market 2025: Rising Prevalence Of Migraine Drives …
"What Is the Forecasted Market Size and Growth Rate for the Migraine Market?
The migraine market is projected to grow steadily from $1.93 billion in 2024 to $1.97 billion in 2025, at a CAGR of 2.2%. This growth is attributed to the rising prevalence of migraines, growing awareness of treatment options, government initiatives, increased alcohol consumption, and lifestyle changes.
Migraine Market: Expected to grow to $2.25 billion by 2029 at a CAGR…
How Big is Migraine Drugs Market?
In 2022, the Global Migraine Drugs Market soared to USD 10,972.1 million, marking a significant milestone. Projections indicate a promising trajectory, with expectations set for substantial growth, potentially reaching USD 26,618.96 million by 2031. Forecasts for the period between 2024 and 2031 suggest a robust Compound Annual Growth Rate (CAGR) of 12.1% for the migraine drugs market.
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive…
Migraine Therapeutics Market - Relieve the Burden: Empowering Lives through Migr …
Newark, New Castle, USA - new report, titled Migraine Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Migraine Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Migraine Therapeutics market. The report offers an overview of the market, which…
Rise in Prevalence of Migraine Drives the Migraine Drugs Market | Outlook 2025
Migraine is characterized by a recurrent throbbing headache, which affects only one side of the head. It is accompanied by vomiting, nausea and even altered vision in some cases.
The increase in the prevalence of migraine, the rapid increase in the female population and the increased awareness among patients for the treatment and prevention of migraine are driving the growth of the global market for anti-migraine drugs.
Get Access to TOC /…
